All manuscripts
Publications TIL Cells G-Rex®10

Expansion of tumor-infiltrating lymphocytes (TIL) from human pancreatic tumors

Published Journal Journal for ImmunoTherapy of Cancer

Share
12 pages Expansion of tumor-infiltrating lymphocytes (TIL) from human pancreatic tumors — Journal for ImmunoTherapy of Cancer, 2016

Overview

The study demonstrates successful expansion of tumor-reactive TILs from pancreatic cancer. The Rapid Expansion Protocol (REP) was performed using GREX10 to stimulate and expand the TILs with anti-CD3 and feeder cells.

What this paper found

Tumor-infiltrating lymphocytes can be grown from surgically resected pancreatic adenocarcinoma, and the cells are functional against pancreatic tumor targets. Fragments from 20 patients were cultured in 6000 IU/mL IL-2, and growth occurred in 19 of 20 tumors (95%). Cultures were mostly CD4+ (mean 66.1%), with a mean of 1.79 × 10^7 TIL per patient and few regulatory T cells (about 4%). Three samples underwent a full two-week rapid expansion with an average 964-fold increase. Adding PD-1 blocking antibody raised yield 2.5-fold, and a 4-1BB agonist raised yield 3.5-fold and CD8+ TIL 23-fold. CD8-enriched TIL released more IFN-γ with HLA-matched pancreatic tumor lines than with mismatched lines.

Note: Autologous tumor targets were not available, so reactivity was tested against HLA-matched pancreatic tumor cell lines; the authors note that methods to establish autologous tumor targets still need to be developed.

TIL were readily isolated and expanded from pancreatic tumors and characterized by a predominantly activated phenotype, rather than the suppressor phenotype previously reported to be present in the tumor microenvironment. — MacLean Hall, Hao Liu, Mokenge Malafa, Barbara Centeno, Pamela J. Hodul, José Pimiento, Shari Pilon-Thomas, Amod A. Sarnaik, Journal for ImmunoTherapy of Cancer

Study details

Authors
MacLean Hall, Hao Liu, Mokenge Malafa, Barbara Centeno, Pamela J. Hodul, José Pimiento, Shari Pilon-Thomas, Amod A. Sarnaik
Institution
Department of Immunology, H Lee Moffitt Cancer Center and Research Institute, Tampa, FL, USA · Gastrointestinal Oncology Program, H Lee Moffitt Cancer Center and Research Institute, Tampa, FL, USA · Cutaneous Oncology Program, H Lee Moffitt Cancer Center and Research Institute, Tampa, FL, USA
Journal
Journal for ImmunoTherapy of Cancer
Year
2016
PMID / PMC
PMID: 27777771 · PMC
G-Rex® model(s)
G-Rex®10
Cell type(s)
TIL Cells
Application area
Solid tumor
Study phase
Preclinical

How G-Rex® was used

The rapid expansion protocol used a GREX10 flask. Pancreatic TIL (5.0 × 10^5) were stimulated with 30 ng/mL anti-CD3 (OKT3) in the presence of 1.0 × 10^8 irradiated allogeneic PBMC feeder cells. Cells grew in 20 mL of 50% REP Media I and 50% AIM V with 3000 IU/mL rhIL-2. On day 4, 10 mL of the same medium was added, and on day 7 cultures were counted, split as needed and topped up with AIM V plus IL-2. After 14 days TIL were collected; three samples averaged 964-fold expansion.

Explore related

Full citation

Hall M, Liu H, Malafa M, et al. Expansion of tumor-infiltrating lymphocytes (TIL) from human pancreatic tumors. J Immunother Cancer. 2016;4:61.

Building a similar workflow?

Talk to a ScaleReady specialist about how the G-Rex® platform can support your program — from process development to clinical-scale manufacturing.

Start a conversation →